CYDY (CytoDyn) Total Inventories: $0.00 Mil (As of Feb. 2026)


CYDY CytoDyn Inc CYDY
28 GF Score
Price $0.25
! 1 Warning Sign
View Full Analysis

What is CytoDyn Total Inventories?

CytoDyn CYDY -0.48% 28 Total Inventories is $0.00 Mil as of Feb. 2026. GuruFocus rates CYDY with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

CytoDyn's total inventories for the quarter that ended in Feb. 2026 was $0.00 Mil. CytoDyn's average total inventories from the quarter that ended in Nov. 2025 to the quarter that ended in Feb. 2026 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. CytoDyn's Net-Net Working Capital per share for the quarter that ended in Feb. 2026 was $-0.08.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CytoDyn  (OTCPK:CYDY) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

CytoDyn's Net-Net Working Capital Per Share for the quarter that ended in Feb. 2026 is

Net-Net Working Capital Per Share (Q: Feb. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(15.655+0.75 * 0+0.5 * 0-122.784
-0-0)/1357.956
=-0.08

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CytoDyn's Days Inventory for the three months ended in Feb. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Feb. 2026 )/Cost of Goods Sold (Q: Feb. 2026 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

CytoDyn's Inventory Turnover for the quarter that ended in Feb. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Feb. 2026 ) / Average Total Inventories (Q: Feb. 2026 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CytoDyn's Inventory to Revenue for the quarter that ended in Feb. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Feb. 2026 ) / Revenue (Q: Feb. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

CytoDyn Total Inventories Related Terms

CytoDyn Total Inventories Historical Data

* Premium members only.

The historical data trend for CytoDyn's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Total Inventories Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 93.48 0.00 0.00 0.00 0.00

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CYDY
28GF Score
CytoDyn Inc CYDY
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
CytoDyn (CYDY) has a Total Inventories of $0.00 Mil as of Feb. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for CytoDyn and its competitors.
Is CytoDyn's Total Inventories too high?
CytoDyn's current Total Inventories is $0.00 Mil. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Total Inventories compare to ZURA and XFOR?
CytoDyn's Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for CytoDyn and its competitors. CytoDyn's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (CYDY) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For CytoDyn (CYDY), the current Total Inventories is $0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges 296:Germany
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for CYDY

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price